Free Trial

89bio Q4 2023 Earnings Report

89bio logo
$6.31 +0.22 (+3.61%)
As of 01/17/2025 04:00 PM Eastern

89bio EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q4 2023
Time
After Market Closes

89bio Earnings Headlines

89bio’s Pegozafermin: Promising Strategic Outlook and Phase 3 Developments
We recommended Palantir in 2021, now we’re recommending this...
I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.
89bio provides business update, outlook 2025
89bio Provides Business Update and Outlook for 2025
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat